Biotech

Latest Articles

Basilea ratings $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's work establishing brand-new antifungals has actually gotten a considerable ...

Capricor offers Europe rights to late-stage DMD therapy for $35M

.Having currently gathered up the USA civil rights to Capricor Therapeutics' late-stage Duchenne mus...

FDA fragments adcomm for Applied's unusual condition medicine

.After pushing the decision date for Applied Rehabs' metabolic condition medicine govorestat, the FD...

Novo inks $600M NanoVation bargain to research hereditary drugs ex-liver

.Novo Nordisk is proceeding its press right into hereditary medicines, accepting compensate NanoVati...

Innovent hyperlinks cytokine to intestines cancer actions

.Innovent Biologics has made the instance that its gate inhibitor-cytokine fusion healthy protein ha...

Merck, Daiichi ADC attacks target in period 3 lung cancer cells research study

.A period 3 test of Daiichi Sankyo and also Merck &amp Co.'s HER3-directed antibody-drug conjugate (...

Rakovina deepens AI concentrate with collab to select cancer intendeds

.Five months after Rakovina Rehabs turned towards artificial intelligence, the cancer-focused biotec...

Ascendis' dwarfism drug hits in phase 3, endangers BioMarin

.Ascendis Pharma has actually emerged as a prospective threat to BioMarin's Voxzogo, stating phase 3...

Despite ph. 3 overlook, Alkeus views pathway in advance for eye disease resource

.Though Alkeus Pharmaceuticals' oral eye health condition property neglected to substantially lessen...

Kairos goes social with $6M IPO to money trials of cancer cells medication

.With a triad of biotechs reaching the Nasdaq on Friday, it was quick and easy to overlook a smaller...

Vaccine and also Keytruda combination successful in squamous cell cancer

.Immune system gate preventions are the superheroes of cancer therapy. Medications like Bristol Myer...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial management hirings, shootings...

Regeneron's Opdualag rival reveals 57% reaction rate

.Regeneron is back along with long-lasting follow-up for its LAG-3 prevention as well as PD-1 preven...

AstraZeneca messages information on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early look at the performance of its internal antibody-drug conj...

iTeos- GSK's TIGIT star presents significant renovation

.After announcing a phase 3 launch based on beneficial midstage outcomes, iTeos and also GSK are fin...

More collective FDA may speed up rare health condition R&ampD: document

.The FDA ought to be a lot more available as well as joint to release a surge in commendations of ra...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It's an uncommonly occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX as well as Bic...

Atea's COVID antiviral neglects to stop hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has actually fallen short an additional COVID-19 test, yet the biot...

Neurocrine's bid to conserve mental illness prospect falls short

.Neurocrine Biosciences' schizophrenia system pivot has actually stopped working. The biotech was ac...

Sanofi pays for $110M upfront for late-stage radioligand therapy

.Sanofi has actually brought in a late access to the radioligand celebration, paying out 100 thousan...